Evidence map›Paper›PMID 20393308›Full record

ArticleGenetics in medicine : official journal of the American College of Medical Genetics2010

Impact of gene patents and licensing practices on access to genetic testing for cystic fibrosis.

Subhashini Chandrasekharan, Christopher Heaney, Tamara James, Chris Conover, Robert Cook-Deegan

Abstract read
In one paragraph

Article in Genetics in medicine : official journal of the American College of Medical Genetics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Gene patents: a broken incentives system.Journal of religion and health · 2013
    Review
  4. Cystic Fibrosis Patents: A Case Study of Successful Licensing.LES nouvelles. Licensing Executives Society (U.S.A.) · 2013
    Article
  5. Article
  6. Article
  7. Patents in genomics and human genetics.Annual review of genomics and human genetics · 2010
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Subhashini ChandrasekharanCenter for Public Genomics, Center for Genome Ethics, Law and Policy, Institute for Genome Sciences and Policy, Duke University, Durham, NC 27708, USA. shubha.c@duke.edu
Christopher Heaney
Tamara James
Chris Conover
Robert Cook-Deegan

Funding

The Management and Organization Core will be administered by the Center for GenomP50HG003391 · NHGRI · DUKE UNIVERSITY · PI BESKOW, LAURA M. · 2004 to 2014
$9.9M
NHGRI NIH HHS P50 HG003391
6 · The paper itself

Abstract

Cystic fibrosis is one of the most commonly tested autosomal recessive disorders in the United States. Clinical cystic fibrosis is associated with mutations in the CFTR gene, of which the most common mutation among Caucasians, DeltaF508, was identified in 1989. The University of Michigan, Johns Hopkins University, and the Hospital for Sick Children, where much of the initial research occurred, hold key patents on cystic fibrosis genetic sequences, mutations, and methods for detecting them. Several patents, including the one that covers detection of the DeltaF508 mutation, are jointly held by the University of Michigan and the Hospital for Sick Children in Toronto, with Michigan administering patent licensing in the United States. The University of Michigan broadly licenses the DeltaF508 patent for genetic testing with >60 providers of genetic testing to date. Genetic testing is now used in newborn screening, diagnosis, and for carrier screening. Interviews with key researchers and intellectual property managers, a survey of laboratories' prices for cystic fibrosis genetic testing, a review of literature on cystic fibrosis tests' cost-effectiveness, and a review of the developing market for cystic fibrosis testing provide no evidence that patents have significantly hindered access to genetic tests for cystic fibrosis or prevented financially cost-effective screening. Current licensing practices for cystic fibrosis genetic testing seem to facilitate both academic research and commercial testing. More than 1000 different CFTR mutations have been identified, and research continues to determine their clinical significance. Patents have been nonexclusively licensed for diagnostic use and have been variably licensed for gene transfer and other therapeutic applications. The Cystic Fibrosis Foundation has been engaged in licensing decisions, making cystic fibrosis a model of collaborative and cooperative patenting and licensing practice.

Indexed as

GenesGenetic TestingHealth Services AccessibilityLicensurePatents as TopicCost-Benefit AnalysisCystic FibrosisFemaleHealth Care CostsHumansInfant, NewbornMaleMutationPregnancyPreimplantation Diagnosis

Identifiers

PMID20393308
PMCPMC2914455

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.